ProQR Q2 revenue and EPS miss estimates
Overview
ProQR Q2 revenue and EPS miss analysts' expectations, per LSEG data
Co submitted CTA for AX-0810, targeting NTCP for cholestatic diseases
ProQR holds EUR119.8 mln cash, providing runway into mid-2027
Outlook
ProQR expects initial AX-0810 Phase 1 data in Q4 2025
Company anticipates AX-2402 clinical candidate selection in 2025
ProQR's cash runway extends into mid-2027, excluding Lilly milestones
Result Drivers
LILLY PARTNERSHIP - Achieved milestones in collaboration with Eli Lilly, contributing €1.8 mln to revenue
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | EUR 3.82 mln | EUR 4.45 mln (7 Analysts) |
Q2 EPS | Miss | -EUR 0.12 | -EUR 0.08 (7 Analysts) |
Q2 Net Income | Miss | -EUR 12.18 mln | -EUR 8.99 mln (6 Analysts) |
Q2 Operating Income | Miss | -EUR 12.25 mln | -EUR 8.77 mln (5 Analysts) |
Q2 Basic EPS | -EUR 0.12 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for ProQR Therapeutics NV is $9.00, about 77.1% above its August 6 closing price of $2.06
Press Release:
